A detailed history of Ubs Group Ag transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 50,868 shares of JANX stock, worth $2.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,868
Previous 22,204 129.09%
Holding current value
$2.77 Million
Previous $835,000 155.09%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$35.12 - $64.78 $1.01 Million - $1.86 Million
28,664 Added 129.09%
50,868 $2.13 Million
Q1 2024

May 13, 2024

BUY
$7.93 - $49.75 $176,077 - $1.1 Million
22,204 New
22,204 $835,000
Q1 2023

May 12, 2023

BUY
$11.25 - $22.21 $7,065 - $13,947
628 Added 294.84%
841 $10,000
Q4 2022

Feb 08, 2023

BUY
$11.1 - $18.26 $2,364 - $3,889
213 New
213 $2,000
Q2 2022

Aug 10, 2022

SELL
$9.52 - $15.65 $33,320 - $54,775
-3,500 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$13.24 - $20.24 $2,449 - $3,744
-185 Reduced 5.02%
3,500 $50,000
Q4 2021

Feb 14, 2022

BUY
$15.44 - $27.32 $2,856 - $5,054
185 Added 5.29%
3,685 $73,000
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $65,142 - $109,169
3,147 Added 891.5%
3,500 $76,000
Q2 2021

Aug 13, 2021

BUY
$18.58 - $25.37 $6,558 - $8,955
353 New
353 $9,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.